PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Name:
PIIS2405630818300491.pdf
Size:
1.052Mb
Format:
PDF
Description:
Full text, Open Access article
Authors
Dillon, MBoylan, Z
Smith, D
Guevara, J
Mohammed, K
Peckitt, C
Saunders, Mark P
Banerji, U
Clack, G
Smith, S
Spicer, J
Forster, M
Harrington, K
Affiliation
The Institute of Cancer Research, London, UKThe Royal Marsden NHS Foundation Trust, London, UKIssue Date
2018-08
Metadata
Show full item recordAbstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.Citation
PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. 2018, 12: 16-20 Clin Transl Radiat OncolJournal
Clinical and Translational Radiation OncologyDOI
10.1016/j.ctro.2018.06.001PubMed ID
30073210Type
ArticleLanguage
enISSN
2405-6308ae974a485f413a2113503eed53cd6c53
10.1016/j.ctro.2018.06.001